CAC
Cowen and Company’s Protagonist Therapeutics PTGX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-340,974
| Closed | -$15.3M | – | 200 |
|
|
2024
Q3 | $15.3M | Sell |
340,974
-841,294
| -71% | -$37.9M | 0.52% | 28 |
|
|
2024
Q2 | $41M | Sell |
1,182,268
-375,368
| -24% | -$13M | 1.13% | 15 |
|
|
2024
Q1 | $45.1M | Buy |
+1,557,636
| New | +$45.1M | 1.75% | 9 |
|
|
2023
Q4 | – | Sell |
-1,657,551
| Closed | -$27.6M | – | 631 |
|
|
2023
Q3 | $27.6M | Hold |
1,657,551
| – | – | 1.93% | 11 |
|
|
2023
Q2 | $45.8M | Buy |
+1,657,551
| New | +$45.8M | 3.79% | 4 |
|
|
2022
Q3 | – | Sell |
-1,065,724
| Closed | -$8.43M | – | 699 |
|
|
2022
Q2 | $8.43M | Buy |
1,065,724
+343,149
| +47% | +$2.71M | 0.81% | 30 |
|
|
2022
Q1 | $17.1M | Buy |
722,575
+719,397
| +22,637% | +$17M | 1.65% | 14 |
|
|
2021
Q4 | $109K | Buy |
+3,178
| New | +$109K | 0.01% | 305 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 474 |
|